Literature DB >> 9801898

The development of malignant rhabdoid tumor in a patient with Behçet's disease treated with ciclosporin.

M Muramatsu1, S Kotake, K Yoshikawa, Y Sasamoto, H Matsuda, S Yamawaki.   

Abstract

PURPOSE: To describe a risk of malignant neoplasm in patients with Behçet's disease treated with ciclosporin.
METHODS: Case report.
RESULTS: A patient with Behçet's disease who was treated with ciclosporin developed a mass in his right femur. Histological examination revealed this mass was a malignant rhabdoid tumor.
CONCLUSION: This is the first known case of malignant tumor developing in a patient with Behçet's disease treated with ciclosporin. This case underscores the importance of assessing possible risks in the treatment of Behçet's disease with ciclosporin.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9801898     DOI: 10.1007/s004170050162

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  5 in total

Review 1.  Cytotoxic T-cell lymphoma arising in Behçet disease.

Authors:  Yukitaka Katsura; Kazumi Suzukawa; Hiroshi Kojima; Chikashi Yoshida; Seiichi Shimizu; Harumi Mukai; Yuichi Hasegawa; Shigehiko Imagawa; Naoyoshi Mori; Toshiro Nagasawa
Journal:  Int J Hematol       Date:  2003-04       Impact factor: 2.490

2.  Cyclosporin-A associated malignancy.

Authors:  Jonathan M Durnian; Rosalind M K Stewart; Richard Tatham; Mark Batterbury; Stephen B Kaye
Journal:  Clin Ophthalmol       Date:  2007-12

3.  Surgery and actinomycin improve survival in malignant rhabdoid tumor.

Authors:  Ryan Horazdovsky; J Carlos Manivel; Edward Y Cheng
Journal:  Sarcoma       Date:  2013-02-03

4.  Morbidity of solid cancer in Behςet's disease: analysis of 11 cases in a series of 506 patients.

Authors:  So Young Na; Jaeyoung Shin; Eun-So Lee
Journal:  Yonsei Med J       Date:  2013-07       Impact factor: 2.759

5.  Rhabdomyosarcoma in a child with nephrotic syndrome treated with cyclosporine: a case report with literature review.

Authors:  Huai-Chueh Gem Wu; Chao-Neng Cheng; Jiann-Shiuh Chen; Yuan-Yow Chiou
Journal:  BMC Nephrol       Date:  2020-11-17       Impact factor: 2.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.